1259438-60-2

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dichloro-5-fluoro-3-methylquinoline serves as an intermediate in the synthesis of pharmaceutical drugs. Its biological activity and potential therapeutic applications have been studied, particularly for the development of anti-cancer and anti-inflammatory medications. 2,4-dichloro-5-fluoro-3-methylquinoline's unique structure and properties make it a valuable component in the creation of novel and effective pharmaceuticals.
Used in Agrochemical Industry:
In addition to its pharmaceutical applications, 2,4-dichloro-5-fluoro-3-methylquinoline is also utilized as an intermediate in the synthesis of agrochemicals. Its chemical properties and reactivity contribute to the development of new and improved agrochemical products, enhancing crop protection and yield.
Used in Production of Functional Materials and Fine Chemicals:
2,4-dichloro-5-fluoro-3-methylquinoline is a valuable building block for the production of various functional materials and fine chemicals. Its unique structure and properties allow it to be incorporated into a wide range of applications, from advanced materials to specialty chemicals, broadening its utility and impact across different industries.

Upstream product

• 1259438-55-5 ethyl 3-(3-fluorophenylamino)-2-methyl-3-oxopropanoate 
• 372-19-0 meta-fluoroaniline 
• 1259438-56-6 3-(3-fluorophenylamino)-2-methyl-3-oxopropanoic acid 

Relevant academic research and scientific papers

Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors

Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors. The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochemical properties and pharmacokinetic profile for animal studies. Analogue 63 was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis. These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a number of inflammatory diseases.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.